Study of adebelimumab and apatinib for extensive stage small cell lung cancer maintenance
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding two targeted therapies (adebelimumab, an immunotherapy, and apatinib, a drug that blocks blood vessel growth) after initial chemotherapy can help keep extensive stage small cell lung cancer under control. It is for people who have not yet had systemic treatment for their cancer and are in good enough health to try this maintenance approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with extensive stage small cell lung cancer (cancer that has spread beyond one lung).
- You have not had any previous treatment for this cancer (like chemotherapy, targeted therapy, or immunotherapy).
- You are able to take oral medications (no swallowing problems or major stomach issues).
- You do not have active autoimmune disease or a history of certain autoimmune conditions.
- You have normal kidney, liver, and blood function, and your blood pressure is controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs as a maintenance therapy after initial chemotherapy for extensive-stage small cell lung cancer. It aims to see if this combination can help keep the cancer from growing.
This study tests a combination of two chemotherapy drugs (irinotecan liposome and a platinum drug) plus an immunotherapy drug and a targeted therapy (anlotinib) as maintenance treatment after initial chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination keeps the cancer from growing for as long as possible.
This study tests a new maintenance therapy (adebrelimab plus apatinib) for people with extensive-stage small cell lung cancer who have already responded to initial chemotherapy and immunotherapy. The goal is to help keep the cancer from coming back longer.
This trial tests a new combination of two targeted/immune drugs with standard chemotherapy as a first treatment for extensive small cell lung cancer. It aims to see if this approach is safe and effective for people who have not had prior treatment for this cancer.
This trial tests a combination of two drugs (adebrelimab and etoposide capsules) as maintenance therapy for people with extensive-stage small cell lung cancer who have not progressed after initial treatment. It may help extend the time before the cancer grows back.
This trial tests a new combination of an immunotherapy drug (adebelimab) with chemotherapy as a first treatment for extensive-stage small cell lung cancer. It aims to see if this combination can help control the cancer better than standard care.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.